Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI

[1]  J. Mayer.  Contents , 2023, The American Journal of Clinical Nutrition.

[2]  E. Bruckert,et al.  Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study , 2022, European heart journal. Quality of care & clinical outcomes.

[3]  K. Ray,et al.  TRS2P and LDL-C alone or in combination for predicting absolute benefits from additional LDL-C lowering: Analysis from the TNT trial. , 2021, Atherosclerosis.

[4]  E. Hagström,et al.  Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study , 2020, European heart journal.

[5]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[6]  S. Al-Shamsi,et al.  Validation of the REduction of Atherothrombosis for Continued Health (REACH) prediction model for recurrent cardiovascular disease among United Arab Emirates Nationals , 2020, BMC Research Notes.

[7]  A. Parkhomenko,et al.  EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. , 2020, European journal of preventive cardiology.

[8]  N. Wong,et al.  The Evolving Understanding and Approach to Residual Cardiovascular Risk Management , 2020, Frontiers in Cardiovascular Medicine.

[9]  M. Danese,et al.  Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom. , 2020, European journal of preventive cardiology.

[10]  E. Vicaut,et al.  A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. , 2019, The New England journal of medicine.

[11]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[12]  W. Aronow.  Faculty Opinions recommendation of Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[13]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[14]  Lawrence A Leiter,et al.  Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy , 2019, European journal of preventive cardiology.

[15]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[16]  Deepak L. Bhatt,et al.  Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. , 2019, Journal of the American College of Cardiology.

[17]  J. Danesh,et al.  Mendelian Randomization Study of ACLY and Cardiovascular Disease , 2019, The New England journal of medicine.

[18]  M. Betts,et al.  Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  K. Khunti,et al.  Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. , 2018, JAMA network open.

[20]  J Wouter Jukema,et al.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.

[21]  B. Lewis,et al.  Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER , 2018, Circulation.

[22]  R. Giugliano,et al.  Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes Vytorin Efficacy International Trial) , 2018, Circulation.

[23]  Marc P. Bonaca,et al.  Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.

[24]  Matthew R. Reynolds,et al.  Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease , 2017, JAMA cardiology.

[25]  C. Cannon,et al.  Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration , 2017, European heart journal.

[26]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[27]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[28]  A. Guerrero,et al.  2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive Summary , 2016, ASEAN heart journal : Official journal of the ASEAN Federation of Cardiology.

[29]  M. Lothgren,et al.  Abstract 18114: Differences Between Observed and Predicted Cardiovascular Event Rates Using the Framingham and REACH Equations: The Case of High-intensity Statin Users in the United Kingdom , 2015 .

[30]  R. Giugliano,et al.  Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT , 2015, Circulation.

[31]  Deepak L. Bhatt,et al.  An international model to predict recurrent cardiovascular disease. , 2012, The American journal of medicine.

[32]  K. Blake,et al.  Increasing scientific standards, independence and transparency in post‐authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance , 2012, Pharmacoepidemiology and drug safety.

[33]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[34]  W. Aronow.  Faculty Opinions recommendation of Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. , 2006 .

[35]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[36]  R. Joynt.  Department , 1960, Neurology.

[37]  Basmah K. Alwahhabi.  Endocrinology , 1925, Saudi Medical Journal.

[38]  OUP accepted manuscript , 2022, European Heart Journal - Quality of Care and Clinical Outcomes.

[39]  Bratislava, Slovakia , 2019, The Statesman’s Yearbook Companion.

[40]  Pigi Kouki,et al.  NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS , 2014 .

[41]  M. Taskinen,et al.  ESC/EAS Guidelines for the Management of Dyslipidaemias , 2013 .

[42]  B. J. Gersh.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2011 .

[43]  P. Barter,et al.  Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). , 2010, The American journal of cardiology.

[44]  J. Provencio.  High-Dose Atorvastatin after Stroke or Transient Ischemic Attack , 2007 .

[45]  W. Howard.  Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. , 2007, Journal of vascular surgery.